Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19

Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU)...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2020-10, Vol.64 (11)
Main Authors: Lê, Minh Patrick, Le Hingrat, Quentin, Jaquet, Pierre, Wicky, Paul-Henri, Bunel, Vincent, Massias, Laurent, Visseaux, Benoit, Messika, Jonathan, Descamps, Diane, Mal, Hervé, Timsit, Jean-François, Peytavin, Gilles
Format: Article
Language:English
Subjects:
Antiviral Agents
COVID-19
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir’s metabolite (GS-441524) and sulfobutylether β-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19).
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.01521-20